Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Baxter
Colorcon
McKinsey
Johnson and Johnson

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

VIIBRYD Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Viibryd, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Allergan Sales Llc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-two patent family members in thirty-two countries.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

Drug patent expirations by year for VIIBRYD
Drug Prices for VIIBRYD

See drug prices for VIIBRYD

Drug Sales Revenue Trends for VIIBRYD

See drug sales revenues for VIIBRYD

Generic Entry Opportunity Date for VIIBRYD
Generic Entry Date for VIIBRYD*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VIIBRYD

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Forest LaboratoriesPhase 1
New York State Psychiatric InstitutePhase 4
Forest LaboratoriesPhase 3

See all VIIBRYD clinical trials

Recent Litigation for VIIBRYD

Identify potential future generic entrants

District Court Litigation
Case NameDate
Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc.2015-11-23
Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc.2015-03-30
Forest Laboratories LLC v. Accord Healthcare Inc.2015-03-27

See all VIIBRYD litigation

PTAB Litigation
PetitionerDate
Argentum Pharmaceuticals LLC2018-01-05

See all VIIBRYD litigation

Synonyms for VIIBRYD
1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride
1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine hydrochloride
1-[4-(5-cyanoindol-3-yl)butyl]4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride
163521-08-2
2-Benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1)
2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride
2794AH
4-(2-carbamoyl-1-benzofuran-5-yl)-1-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-ium chloride
5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide hydrochloride
5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide monohydrochloride
5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2carboxamide hydrochloride
5-[4-[4-(5-Cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide hydrochloride
5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide hydrochloride
5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide;hydrochloride
5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride
5-[4-[4-(5-Cyanoindol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride
5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide hydrochloride
521V128
A3919
AB0000947
AC-25885
AC1OCFA0
AK161007
AKOS024464039
AN-5344
API0009252
AX8294006
BCP11496
C26H27N5O2.ClH
CCG-213313
CHEBI:70705
CHEMBL1615374
CS-0549
D09699
EBD2199528
EMD 68 843
EMD 68843
EMD-68-843
EMD-68843
EMD68843
HY-14261
J-525160
KB-81444
KS-00000SKE
LS-34922
MolPort-028-744-909
RL02096
RL02097
RPZBRGFNBNQSOP-UHFFFAOYSA-N
s4259
SB 659746A
SB-659746-A
SB-659746A
SB659746-A
SB659746A
SCHEMBL867358
ST24050347
SW219887-1
U8HTX2GK8J
UNII-U8HTX2GK8J
Viibryd (TN)
Vilazodone (Hydrochloride)
Vilazodone HCl
Vilazodone hydrochloride
Vilazodone hydrochloride (USAN)
Vilazodone hydrochloride [USAN]
Vilazodone hydrochloride solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Vilazodone hydrochloride, >=98% (HPLC)
vilazodone monohydrochloride
Vilazodonei
Paragraph IV (Patent) Challenges for VIIBRYD
Tradename Dosage Ingredient NDA Submissiondate
VIIBRYD TABLET;ORAL vilazodone hydrochloride 022567 2015-01-21

US Patents and Regulatory Information for VIIBRYD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIIBRYD

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011   Start Trial   Start Trial
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011   Start Trial   Start Trial
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Moodys
Johnson and Johnson
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.